Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNK-UT Cells for Relapsed/Refractory Neuroblastoma
NCT06751134Phase 1Recruiting
- Sponsor
- Children's Hospital of Nanjing Medical University
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNK-UT001 in neuroblastoma, sponsored by Children's Hospital of Nanjing Medical University. Primary endpoint: Incidence of Treatment Related adverse events at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
CNK-UT001
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06751134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751134.